TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01386372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Fluid restriction, normal or hypertonic saline, furosemide.
Study: NCT00252382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-595 Injection
Description: Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
Study: NCT00776139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet
Study: NCT03028285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine sodium succinate
Description: Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine sodium succinate
Description: Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine sodium succinate
Description: Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
Study: NCT03075683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation
Description: Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
Study: NCT01154504

Intervention type: OTHER
Group type: OTHER
Intervention: clinical treatment
Description: The clinical treatment will be optimized to gold standard international heart failure treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrafiltration
Description: The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: isovolumetric hemofiltration
Description: The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
Study: NCT00714207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOT program
Description: Students in this arm of the study received the reformatted NOT intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NOT controls
Description: Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kicking Butts intervention
Description: Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
Study: NCT05926219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatiguing Exercise
Description: Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
Study: NCT00582231

Intervention type: OTHER
Intervention: Questionnaires.
Description: Questionnaires.
Study: NCT03997266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Intravenous ampicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamycin
Description: Intravenous gentamycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous normal saline
Study: NCT03249831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Initially IV. If patient tolerates, convert to oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: IV or oral
Study: NCT00921908

Intervention type: OTHER
Intervention: 2 mBq radioactive technetium diluted in 20 mL saline
Study: NCT00714207

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KB controls
Description: Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
Study: NCT02223728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Study: NCT01245972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDL Treatment
Description: Pulsed-dye laser (PDL) treatment at one of two settings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDL Treatment
Description: Pulsed-dye laser (PDL) treatment at one of two settings.
Study: NCT03983304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The EMS device will be used to perform the treatments.
Study: NCT01628458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation (RFA)
Description: RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
Study: NCT02870348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
Study: NCT00578396

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grapes
Description: 1 pound of seedless red grapes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grapes
Description: 2/3 lb/day fresh red grapes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grapes
Description: 1/3 lb/day fresh red grapes
Study: NCT05364658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvene IOL
Description: Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
Study: NCT03511924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic resistance training
Description: Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
Study: NCT02499640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times
Study: NCT06054594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
Study: NCT00416663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous ACPs
Description: Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
Study: NCT04028765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
Study: NCT04175912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study: NCT03315910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: two counseling sessions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenge
Description: 6 packs of NRT 2mg lozenge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Framing
Description: health communication literature and quitting messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva samples from those reporting abstinence and analyze samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva samples from those reporting abstinence and analyze samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva samples from those reporting abstinence and analyze samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva samples from those reporting abstinence and analyze samples
Study: NCT00297895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Completion Lymphadenectomy
Description: complete lymph node dissection of lymph node basin with positive node

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring with nodal ultrasound
Description: serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
Study: NCT03249831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Description: Infusion
Study: NCT01404286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Study: NCT02223728

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Study: NCT04056754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
Study: NCT03643276

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Part of standard chemotherapy
Study: NCT01654094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P6 Low Adherent Dressing
Description: Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
Study: NCT03683446

Intervention type: PROCEDURE
Intervention: Laparoscopic rectal surgery
Description: Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.

Intervention type: PROCEDURE
Intervention: Open rectal surgery
Description: Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
Study: NCT05025189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table Grape Powder
Description: Freeze Dried Whole Table Grape Powder
Study: NCT03840304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga@work
Description: Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
Study: NCT02962895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study: NCT02878525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic internal gastric banding
Description: Laparoscopic internal gastric banding
Study: NCT03643276

Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Part of standard chemotherapy
Study: NCT04056754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects administered 5mg prednisone twice daily in 28-day cycle.
Study: NCT03643276

Intervention type: DRUG
Group type: OTHER
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Part of standard chemotherapy
Study: NCT05025189

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beige Diet
Description: Low Fiber, low polyphenol Diet
Study: NCT00749918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
Study: NCT03857243

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dual transcranial direct current stimulation
Description: Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual transcranial direct current stimulation
Description: Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
Study: NCT00330564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Study: NCT02878525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy
Study: NCT04040595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal fat biopsy
Description: A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
Study: NCT01304212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine,morphine chloride,epinephrine,ketorolac
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine ,ketorolac
Description: ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
Study: NCT02607917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass Media plus clinic intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media
Study: NCT00649623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan Medoxomil Tablets 40 mg
Description: 40mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benicar® Tablets 40 mg
Description: 40mg, single dose fasting